Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
India · Delayed Price · Currency is INR | Market Cap | 4.06T |
| Revenue (ttm) | 525.78B |
| Net Income (ttm) | 109.29B |
| Shares Out | 2.40B |
| EPS (ttm) | 45.55 |
| PE Ratio | 37.15 |
| Forward PE | 32.63 |
| Dividend | 16.00 (0.95%) |
| Ex-Dividend Date | Jul 7, 2025 |
| Volume | 1,088,485 |
| Average Volume | 1,759,554 |
| Open | 1,690.00 |
| Previous Close | 1,692.00 |
| Day's Range | 1,682.20 - 1,702.00 |
| 52-Week Range | 1,553.05 - 1,960.35 |
| Beta | 0.36 |
| RSI | 54.80 |
| Earnings Date | Jul 31, 2025 |
About NSE:SUNPHARMA
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respira... [Read more]
Financial Performance
In 2024, NSE:SUNPHARMA's revenue was 525.78 billion, an increase of 8.42% compared to the previous year's 484.97 billion. Earnings were 109.29 billion, an increase of 14.12%.
Financial StatementsNews
Sun Pharma subsidiaries settle US antitrust litigation for $200 million
Sun Pharmaceutical Industries Limited (“Sun Pharma”) has announced that its subsidiaries, Sun Pharmaceutical Industries, Inc. (“SPII”) and Taro Pharmaceuticals U.S.A., Inc. (“Taro”), have entered into...
Sun Pharma reports positive results from Phase 3 trials for ILUMYA
Sun Pharmaceutical Industries has shared encouraging top-line results from two (Phase 3) clinical trials evaluating its biologic drug tildrakizumab 100 mg, marketed as ILUMYA®, for the treatment of ac...
Tata Technologies, Sun Pharma & more: Top stocks on brokers' radar for July 17, 2025
Brokerage firms have varying outlooks on several companies. JP Morgan downgraded Tata Technologies due to mixed Q1 results, while Goldman Sachs is optimistic about Ola Electric's path to profitability...
Nifty 50 top losers today, July 16: Shriram Finance, Eternal, Sun Pharma, Cipla, Tata Steel and more
Indian stock markets wrapped up July 16 on a quiet but positive note, with both Sensex and Nifty 50 posting modest gains. The Sensex inched up by 63.57 points to end at 82,634.48, while the Nifty 50 a...
Nifty top gainers today, July 15: Hero MotoCorp, Bajaj Auto, Sun Pharma, Shriram Finance, Apollo Hospitals and more
Indian stock markets wrapped up the day on a positive note this Monday, July 15, with both benchmark indices showing solid strength. The BSE Sensex jumped 317 points to close at 82,570.91, while the N...
Sun Pharma Announces Launch of LEQSELVI™ (deuruxolitinib) in the United States for the Treatment of Severe Alopecia Areata
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients MUMBAI, India and PRINCETON, N.J. , July 14, 2025 /PRNewswire/ -- Sun Pharmaceutical Industries ...
Sun Pharma announces settlement with Incyte Corporation over LEQSELVI litigation
Sun Pharmaceutical Industries Ltd announced on July 14 that it has reached a settlement and license agreement with Incyte Corporation in connection with litigation over the drug LEQSELVI™ (deuruxoliti...
Morgan Stanley turns selective on Indian pharma, initiates call on Sun Pharma, Lupin, DRL, CIPLA shares
Morgan Stanley has initiated coverage on India’s four largest pharmaceutical companies by market capitalization — Sun Pharma, Lupin, Dr. Reddy’s Labs (DRL), and Cipla — with a broadly cautious outlook...
Nomura says IPM growth accelerated to 8% in June; IPCA, Sun Pharma lead gains
Nomura has reported that India’s pharmaceutical market (IPM) grew 8% year-on-year in June 2025, driven by a recovery in acute therapies. The growth is the highest recorded in the past five months and ...
Drugs Control Administration (DCA) seizes fake Levipil 500 tablets in major Hyderabad raid
The Drugs Control Administration (DCA) in Hyderabad seized counterfeit Levipil 500 tablets, used for epilepsy treatment, from two pharmaceutical shops. The shops were falsely claiming the tablets were...
Torrent Pharma becomes India’s 5th largest drugmaker
Torrent Pharma's acquisition of JB Chemicals & Pharmaceuticals propels it to become India's fifth-largest pharmaceutical company, capturing a 4.6% market share. This deal significantly strengthens Tor...
Nifty 50 top losers today, June 17: Adani Enterprises, Dr. Reddy’s, Tata Motors, Sun Pharma lead declines
Indian equity benchmarks closed lower on Tuesday, June 17, 2025, as cautious market sentiment weighed on investor confidence. The BSE Sensex dropped 212.85 points (0.26%) to settle at 81,583.30, while...
Nifty 50 top losers today, June 16: Tata Motors, Dr. Reddy’s, Sun Pharma, Adani Ports and Jio Financial Services
Indian equity markets closed on a strong note on June 16, 2025, with broad-based gains across major sectors. The BSE Sensex surged 677.55 points (0.84%) to close at 81,796.15, while the NSE Nifty 50 g...
UBS retains ‘Buy’ on Sun Pharma stock but awaits clarity on US drug tariffs
UBS has maintained a ‘Buy’ rating on Sun Pharmaceutical Industries with a target price of ₹2,450, while flagging near-term regulatory and policy uncertainties. The brokerage noted that Sun Pharma is u...
Stocks to watch on June 17: Syngene, Tata Motors, Vedanta, YES Bank, SpiceJet, Sun Pharma, Natco Pharma, Zydus, Ramkrishna Forging
Here’s a look at the key stocks that could be in focus on June 16 based on company announcements, regulatory updates, promoter actions, and sector movements: Syngene: US FDA issues zero observations f...
Compliance review: Sun Pharma’s Halol plant gets 8 USFDA observations; company vows remedial steps after inspection
Sun Pharmaceutical Industries faces scrutiny. The USFDA issued a Form 483. This follows an inspection of its Halol manufacturing plant in Gujarat. The inspection occurred between June 2 and June 13, 2...
Sun Pharma’s Halol facility receives form 483 with 8 observations from US FDA
Sun Pharmaceutical Industries Limited, one of India’s leading pharmaceutical companies, has announced the conclusion of a recent inspection by the United States Food and Drug Administration (US FDA) a...
Sun Pharma elevates Kirti Ganorkar as MD; Dilip Shanghvi to stay on as exec chairman
Sun Pharma's India business head, Kirti Ganorkar, will become the managing director on September 1, succeeding founder Dilip Shanghvi. Shanghvi will transition to executive chairman, while his son Aal...
Nifty 50 top losers today, June 6: HDFC Life, Bharat Electronics, Bharti Airtel, Tata Steel and Sun Pharma
Indian equity markets ended on a strong note today following a surprise monetary easing by the Reserve Bank of India (RBI). The central bank reduced the repo rate by 50 basis points and cut the Cash R...
SPARC shares drop nearly 20% after key drug trial fails
Shares of Sun Pharma Advanced Research Company (SPARC) declined sharply by nearly 20% after the company announced the discontinuation of clinical trials for its experimental drug Vibozilimod (SCD-044)...
Nifty 50 top gainers today, May 29: IndusInd Bank, Sun Pharmaceutical, Eternal, Adani Ports and Trent
Indian equity markets showcased strong momentum on May 29, with benchmark indices ending the day in the green. The BSE Sensex surged 320.70 points or 0.39%, closing at 81,633.02, while the Nifty 50 ad...
Macquarie sees buying opportunity in pharma, stays bearish on hospital stocks
Macquarie has turned selectively bullish on the healthcare sector following the recent correction in Indian pharma formulation stocks, driven in part by concerns over global tariff threats. The broker...
Nifty 50 top losers today, May 23: Sun Pharmaceutical, Grasim Industries and Bharti Airtel
The Indian equity markets demonstrated robust performance today, May 23, 2025, with key benchmark indices closing firmly in the green. The BSE Sensex surged by 769.09 points, a gain of 0.95%, closing ...
Sun Pharma shares drop over 4% as Q4 misses estimates
Sun Pharmaceutical Industries Ltd. saw its shares drop over 4% in morning trade on Friday after the company announced its Q4 results. As of 9:15 AM, the shares were trading 3.53% lower at Rs 1,658.00....
Stocks in news on May 23: NTPC Green, Tata Steel, Adani Ports, Deepak Fertilizers, Sun Pharma, Ramco Cement, ITC, and more
Mumbai, May 23, 2025 – A flurry of earnings announcements and corporate updates have placed several stocks in focus for today’s trading session. From robust profit growth in sectors like cement, sugar...